戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 es, 7 colonoscopies, 2 endoscopic retrograde cholangiopancreatographies).
2 er endoscopies, and 58 endoscopic retrograde cholangiopancreatographies).
3 cture was confirmed by endoscopic retrograde cholangiopancreatography.
4 iliary stent placed by endoscopic retrograde cholangiopancreatography.
5 ning biliary access at endoscopic retrograde cholangiopancreatography.
6 -Science Conference on endoscopic retrograde cholangiopancreatography.
7 tis in comparison with endoscopic retrograde cholangiopancreatography.
8 uces the incidence of pancreatitis following cholangiopancreatography.
9 iatric experience with endoscopic retrograde cholangiopancreatography.
10 hose at helical CT and endoscopic retrograde cholangiopancreatography.
11  cells obtained during endoscopic retrograde cholangiopancreatography.
12 d tissue sampling with endoscopic retrograde cholangiopancreatography.
13 on the advisability of endoscopic retrograde cholangiopancreatography.
14 om tissue extracted by endoscopic retrograde cholangiopancreatography.
15 pcSEMS (n = 71) during endoscopic retrograde cholangiopancreatography.
16 oth endosonography and endoscopic retrograde cholangiopancreatography.
17  The first description of magnetic resonance cholangiopancreatography, a new noninvasive imaging stud
18 hemoprevention of post-endoscopic retrograde cholangiopancreatography acute pancreatitis and enteral
19 hemoprevention of post-endoscopic retrograde cholangiopancreatography acute pancreatitis remains unpr
20 ET/CT, MDCT, and MR imaging combined with MR cholangiopancreatography, all of which were evaluated in
21                         Specificities for MR cholangiopancreatography alone and for MR cholangiopancr
22 yields higher diagnostic performance than MR cholangiopancreatography alone.
23 ct cholangiography (45 endoscopic retrograde cholangiopancreatography and 1 percutaneous transhepatic
24                        Endoscopic retrograde cholangiopancreatography and balloon trawling of the int
25 tomy was defined using endoscopic retrograde cholangiopancreatography and categorized as a normal duc
26                           Magnetic resonance cholangiopancreatography and endoscopic ultrasound are d
27 ic resonance imaging with magnetic resonance cholangiopancreatography and optional endoscopic ultraso
28              Timing of endoscopic retrograde cholangiopancreatography and outcome were stratified by
29            The combination of T2-weighted MR cholangiopancreatography and T1-weighted imaging yields
30 and endoscopic retrograde/magnetic resonance cholangiopancreatography and the lowest was 1.79% in stu
31 on with the results of endoscopic retrograde cholangiopancreatography and the secretin test.
32 hy, contrast material-enhanced MR imaging/MR cholangiopancreatography, and ASGE risk stratification g
33 ography scan, ultrasound, magnetic resonance cholangiopancreatography, and direct cholangiography.
34 ical computed tomography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography
35 opic retrograde cholangiopancreatography, MR cholangiopancreatography, and fluoroscopy will be demons
36 minal trauma, surgery, endoscopic retrograde cholangiopancreatography, and gallstones.
37 , computed tomography, endoscopic retrograde cholangiopancreatography, and magnetic resonance imaging
38 for pancreatitis after endoscopic retrograde cholangiopancreatography, and refinements in photodynami
39 gnetic resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound.
40 ic ultrasonography and endoscopic retrograde cholangiopancreatography are just beginning to be assess
41                                    CT and MR cholangiopancreatography are the most common cross-secti
42 ng therapeutic role of endoscopic retrograde cholangiopancreatography as well as improvements in our
43 gations in therapeutic endoscopic retrograde cholangiopancreatography as well as knowledge gaps for f
44  of pancreatitis after endoscopic retrograde cholangiopancreatography as well as morbidity in the eld
45 undergoing therapeutic endoscopic retrograde cholangiopancreatography at university hospitals in Euro
46 on guidelines versus magnetic resonance (MR) cholangiopancreatography-based treatment of patients wit
47                        Endoscopic retrograde cholangiopancreatography brushings were obtained from 49
48  that balloon-assisted endoscopic retrograde cholangiopancreatography can achieve papillary cannulati
49                                           MR cholangiopancreatography can depict congenital and acqui
50 iven immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acu
51 any cases, therapeutic endoscopic retrograde cholangiopancreatography can take the place of invasive
52 uted tomography scans, endoscopic retrograde cholangiopancreatography, carcinoembryonic antigen, and
53                        Endoscopic retrograde cholangiopancreatography confirmed the diagnosis and all
54              Pediatric endoscopic retrograde cholangiopancreatography continues to evolve, with incre
55 possible choledocholithiasis: noncontrast MR cholangiopancreatography, contrast material-enhanced MR
56             Sensitivities for T2-weighted MR cholangiopancreatography data alone were 0.65, 0.70, and
57              Timing of endoscopic retrograde cholangiopancreatography does not appear to affect clini
58 EST PRACTICE ADVICE 8: Endoscopic retrograde cholangiopancreatography during pregnancy may be perform
59 SC patients undergoing endoscopic retrograde cholangiopancreatography earlier in their clinical cours
60                           Magnetic resonance cholangiopancreatography enables reliable diagnosis of c
61  software manipulation of magnetic resonance cholangiopancreatography, enabling preoperative VR explo
62 ctor computed tomography, magnetic resonance cholangiopancreatography, endoscopic ultrasonography, an
63 holecystectomies and 4 endoscopic retrograde cholangiopancreatography/endoscopic sphincterotomies (ER
64 ts undergoing elective endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasono
65 inical applications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasoun
66 eviewed the results of endoscopic retrograde cholangiopancreatography (ERCP) and intraoperative chola
67                  While endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhe
68  increased by previous endoscopic retrograde cholangiopancreatography (ERCP) and stent placement, and
69 typically managed with endoscopic retrograde cholangiopancreatography (ERCP) and stenting.
70 erforations related to endoscopic retrograde cholangiopancreatography (ERCP) are rare but life-threat
71 e scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) between March 26, 2008,
72          MRCP obviated endoscopic retrograde cholangiopancreatography (ERCP) by excluding choledochol
73 transmission following endoscopic retrograde cholangiopancreatography (ERCP) can occur due to persist
74 biliary cannulation in endoscopic retrograde cholangiopancreatography (ERCP) can result in failure of
75 th cholangioscopes and endoscopic retrograde cholangiopancreatography (ERCP) catheters.
76 contrast agents during endoscopic retrograde cholangiopancreatography (ERCP) causes pancreatic inflam
77 nostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP) continues to mature.
78 sy and others, such as endoscopic retrograde cholangiopancreatography (ERCP) cytology, are problemati
79 logy/surgical findings/Endoscopic Retrograde CholangioPancreatography (ERCP) findings as applicable.
80  ADVICE 2: The role of endoscopic retrograde cholangiopancreatography (ERCP) for reducing the frequen
81 aphy (EUS) may replace endoscopic retrograde cholangiopancreatography (ERCP) for the detection of CBD
82 ver the past 50 years, endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred
83 mples were obtained at endoscopic retrograde cholangiopancreatography (ERCP) in 59 patients with gall
84  of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients, t
85 ent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients.
86 tent utilized at index endoscopic retrograde cholangiopancreatography (ERCP) in management of maligna
87 he experience of using endoscopic retrograde cholangiopancreatography (ERCP) in the management of hep
88  on the performance of endoscopic retrograde cholangiopancreatography (ERCP) in the United States.
89 opy allows therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in these patients, avoid
90                        Endoscopic retrograde cholangiopancreatography (ERCP) is a technically challen
91                        Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demandi
92                        Endoscopic retrograde cholangiopancreatography (ERCP) is a widely utilized pro
93                        Endoscopic retrograde cholangiopancreatography (ERCP) is important in the mana
94           Preoperative endoscopic retrograde cholangiopancreatography (ERCP) is only useful for patie
95 rmed endoscopically by endoscopic retrograde cholangiopancreatography (ERCP) or by percutaneous trans
96  evaluated by means of endoscopic retrograde cholangiopancreatography (ERCP) or magnetic resonance ch
97 om ductal drainage via endoscopic retrograde cholangiopancreatography (ERCP) or surgical drainage pro
98  the prevention of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.
99 verticulum (PAD) among endoscopic retrograde cholangiopancreatography (ERCP) patients in Southwestern
100                        Endoscopic retrograde cholangiopancreatography (ERCP) plays a significant role
101 d duodenoscopes during endoscopic retrograde cholangiopancreatography (ERCP) procedures.
102  were time to surgery, endoscopic retrograde cholangiopancreatography (ERCP) rates, and postoperative
103 h PSC established with endoscopic retrograde cholangiopancreatography (ERCP) were compared with the M
104 agement often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphin
105                        Endoscopic retrograde cholangiopancreatography (ERCP) with or without sphincte
106 cholithiasis requiring endoscopic retrograde cholangiopancreatography (ERCP) with stone extraction re
107 phy (US), 21 patients; endoscopic retrograde cholangiopancreatography (ERCP), 19 patients; and percut
108 perforation related to endoscopic retrograde cholangiopancreatography (ERCP), a rate of 1.0%.
109 ding, judicious use of endoscopic retrograde cholangiopancreatography (ERCP), and gallbladder surgery
110 sk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from
111 ated and compared with endoscopic retrograde cholangiopancreatography (ERCP), clinical examination, a
112  hospitalization after endoscopic retrograde cholangiopancreatography (ERCP), largely for the evaluat
113 e to humans through an endoscopic retrograde cholangiopancreatography (ERCP), may offer a potential i
114 idental finding during endoscopic retrograde cholangiopancreatography (ERCP), occurring more frequent
115  made with findings at endoscopic retrograde cholangiopancreatography (ERCP), performed within 30 day
116 common complication of endoscopic retrograde cholangiopancreatography (ERCP), resulting in substantia
117  the 2-stage approach [endoscopic retrograde cholangiopancreatography (ERCP), sphincterotomy, and com
118 copic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomogra
119                        Endoscopic retrograde cholangiopancreatography (ERCP), the most commonly perfo
120 eared complications of endoscopic retrograde cholangiopancreatography (ERCP), with an incidence of 3.
121                        Endoscopic retrograde cholangiopancreatography (ERCP)-related adverse events (
122 SC patients undergoing endoscopic retrograde cholangiopancreatography (ERCP).
123  of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).
124 uracy when compared to endoscopic retrograde cholangiopancreatography (ERCP).
125  need for preoperative endoscopic retrograde cholangiopancreatography (ERCP).
126 scopic) have undergone endoscopic retrograde cholangiopancreatography (ERCP).
127 was pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).
128 holithiasis to receive endoscopic retrograde cholangiopancreatography (ERCP).
129  of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).
130  of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).
131 jor complication after endoscopic retrograde cholangiopancreatography (ERCP).
132 nostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP).
133 initiating therapeutic endoscopic retrograde cholangiopancreatography (ERCP).
134 st current therapeutic endoscopic retrograde cholangiopancreatography (ERCP).
135  of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP).
136 sover rate, numbers of endoscopic retrograde cholangiopancreatography (ERCPs) and stents, and stent-
137 copic ultrasonography and magnetic resonance cholangiopancreatography extend the diagnostic power of
138 patients had undergone endoscopic retrograde cholangiopancreatography for attempted relief in the pas
139 patients who underwent endoscopic retrograde cholangiopancreatography for evaluation of malignancy at
140 re destined to replace endoscopic retrograde cholangiopancreatography for many diagnostic indications
141 ve patients undergoing endoscopic retrograde cholangiopancreatography for pancreatobiliary strictures
142 the latest findings on endoscopic retrograde cholangiopancreatography for the evaluation of biliary s
143  Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks).
144    Patients who had an endoscopic retrograde cholangiopancreatography had fewer recurrent biliary eve
145 duodenoscopes used for endoscopic retrograde cholangiopancreatography have highlighted the challenge
146 endoscopic ultrasound and magnetic resonance cholangiopancreatography in chronic pancreatitis diagnos
147 ) correlates well with endoscopic retrograde cholangiopancreatography in moderate to severe chronic p
148 and the performance of endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y gast
149 biliary biopsy) during endoscopic retrograde cholangiopancreatography in the absence of an alternativ
150 arly feeding, avoiding endoscopic retrograde cholangiopancreatography in the absence of concomitant c
151 s the diagnostic value of magnetic resonance cholangiopancreatography in the diagnostics of biliary d
152 endoscopic ultrasound and magnetic resonance cholangiopancreatography in the evaluation of suspected
153                  Patients underwent 1.5-T MR cholangiopancreatography, including DW sequences (b = 0,
154              All subjects underwent 3.0-T MR cholangiopancreatography, including serial DW imaging se
155                        Endoscopic retrograde cholangiopancreatography-induced acute pancreatitis can
156 at diclofenac prevents endoscopic retrograde cholangiopancreatography-induced pancreatitis.
157 ation recommending endoscopy (high risk), MR cholangiopancreatography (intermediate risk), or no test
158                           Magnetic resonance cholangiopancreatography is a cost-effective and accurat
159                        Endoscopic retrograde cholangiopancreatography is a non-surgical approach to d
160 Magnetic resonance imaging with contrast and cholangiopancreatography is a reasonable complementary o
161                           Magnetic resonance cholangiopancreatography is a relatively noninvasive tec
162                        Endoscopic retrograde cholangiopancreatography is commonly performed to remove
163 o be overlooked unless endoscopic retrograde cholangiopancreatography is performed.
164                        Endoscopic retrograde cholangiopancreatography is reserved primarily for thera
165                  MRI with magnetic resonance cholangiopancreatography is the preferred imaging modali
166 phy, magnetic resonance (MR) imaging, and MR cholangiopancreatography, is increasing, and many of the
167 server agreement was good for T2-weighted MR cholangiopancreatography (kappa for readers 1 and 2 = 0.
168 s were correlated with endoscopic retrograde cholangiopancreatography, laboratory parameters, and fib
169    Advancements in the endoscopic retrograde cholangiopancreatography medical literature in the last
170                        Endoscopic retrograde cholangiopancreatography mitigates this risk and should
171 esonance (MR) imaging, endoscopic retrograde cholangiopancreatography, MR cholangiopancreatography, a
172 uted tomography scanning, magnetic resonance cholangiopancreatography (MRCP) and positron emission to
173                           Magnetic resonance cholangiopancreatography (MRCP) is the best test to eval
174 n the study who underwent magnetic resonance cholangiopancreatography (MRCP) studies.
175 concern in Nigeria, where magnetic resonance cholangiopancreatography (MRCP), a non-invasive imaging
176 inal ultrasound, CT, MRI, magnetic resonance cholangiopancreatography (MRCP), and T-tube cholangiogra
177  pancreatic ducts at magnetic resonance (MR) cholangiopancreatography (MRCP), because of an enlargeme
178 nts; magnetic resonance (MR) imaging with MR cholangiopancreatography (MRCP), four patients; endoscop
179 pancreatography (ERCP) or magnetic resonance cholangiopancreatography (MRCP).
180  the pancreatic duct with magnetic resonance cholangiopancreatography (MRCP).
181 tic resonance imaging and magnetic resonance cholangiopancreatography (MRI/MRCP), are helpful in the
182            Subsequently, combined MRI and MR cholangiopancreatography of the abdomen was performed wi
183            Subsequently, combined MRI and MR cholangiopancreatography of the abdomen was performed wi
184 he effect of timing of endoscopic retrograde cholangiopancreatography on clinical outcomes, and compa
185 P = .01), preoperative endoscopic retrograde cholangiopancreatography (OR, 2.07 [95% CI, 1.46-2.92];
186 the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (ERCP) has been di
187 risk of developing postendoscopic retrograde cholangiopancreatography pancreatitis in high-risk peopl
188 the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
189      Enteroscopy-based endoscopic retrograde cholangiopancreatography, percutaneous transhepatic chol
190 experienced hands, and endoscopic retrograde cholangiopancreatography plays a diagnostic as well as t
191                                           MR cholangiopancreatography plays an important role in the
192 rs 1 and 3 = 0.734) and was excellent for MR cholangiopancreatography plus T1-weighted images (kappa
193 MR cholangiopancreatography alone and for MR cholangiopancreatography plus T1-weighted images were hi
194 pancreatitis following endoscopic retrograde cholangiopancreatography presents a unique opportunity f
195 EMS) may require fewer endoscopic retrograde cholangiopancreatography procedures (ERCPs) to achieve r
196 course of 40 weeks via endoscopic retrograde cholangiopancreatography procedures at a single institut
197 minations, and 169,500 endoscopic retrograde cholangiopancreatography procedures were performed annua
198 r tissue analysis, and endoscopic retrograde cholangiopancreatography provided access for dilation, s
199 e biliary obstruction likely benefit from MR cholangiopancreatography rather than risk-stratified dia
200  versus noncontrast and contrast-enhanced MR cholangiopancreatography, respectively, but was also les
201 cohol), gallstones, or endoscopic retrograde cholangiopancreatography result in a cascade of events b
202 mpared with pathology and magnetic resonance cholangiopancreatography results.
203         The results of endoscopic retrograde cholangiopancreatography served as the reference standar
204               Ideally, endoscopic retrograde cholangiopancreatography should be performed during the
205 The bundle states that endoscopic retrograde cholangiopancreatography should be performed within the
206 underwent preoperative endoscopic retrograde cholangiopancreatography since the isolated microorganis
207 ase, MRI, Primary Sclerosing Cholangitis, MR Cholangiopancreatography Supplemental material is availa
208 ce the introduction of endoscopic retrograde cholangiopancreatography, there have been great improvem
209 incremental cost per QALY for noncontrast MR cholangiopancreatography was $10 311.
210                       Results Noncontrast MR cholangiopancreatography was most cost-effective in 45-5
211 tion cohort, timing of endoscopic retrograde cholangiopancreatography was not significantly different
212                                           MR cholangiopancreatography was performed in 37 consecutive
213             Initially, endoscopic retrograde cholangiopancreatography was purely a diagnostic procedu
214                                           MR cholangiopancreatography was successful in all patients.
215  or lipase levels, and endoscopic retrograde cholangiopancreatography was the method of diagnosis of
216 ed and/or known CP who were scheduled for MR cholangiopancreatography, were recruited and gave writte
217 gnostic utilization of endoscopic retrograde cholangiopancreatography which is now reserved primarily
218 essitating an emergent endoscopic retrograde cholangiopancreatography with biliary stenting and decom
219  our hospital where an endoscopic retrograde cholangiopancreatography with biliary stenting was perfo
220 lithiasis treated with endoscopic retrograde cholangiopancreatography with laparoscopic cholecystecto
221  a randomized trial of endoscopic retrograde cholangiopancreatography with SOM for patients with idio
222 k-stratified testing was less costly than MR cholangiopancreatography, with long-term savings of $187
223  stones, postoperative endoscopic retrograde cholangiopancreatography, wound infection, reoperation,

 
Page Top